BNTC Benitec Biopharma Limited

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

 

For the month of November

Commission File Number 001-37518

 

Benitec Biopharma Limited
(Translation of registrant’s name into English)

 

F6A, 1-15 Barr Street
Balmain, NSW 2041
Australia

 (Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F [X] Form 40-F [   ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [   ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [   ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [   ] No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Benitec Biopharma Limited
Date:  11/02/15	By:	/s/ GREG WEST
	Name:	Greg West
	Title:	Company Secretary

 

 

EXHIBIT INDEX

Exhibit Number	Description
99.1	Announcement, dated 10/30/15, to Australian Securities Exchange

 

 

 

Exhibit 99.1

 

ASX ANNOUNCEMENT

 

ASX APPENDIX 4C

 

QUARTERLY CASH FLOW REPORT

 

FOR THE QUARTER ENDED 30 SEPTEMBER 2015

 

 

Sydney Australia, 30 October 2015: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged with ASX the attached Appendix 4C quarterly cash flow report for period ended 30 September 2015.

 

Benitec held $32.4 million in cash at 30 September 2015, compared to $21.8 million at 30 June 2015. Net operating cash flow for the quarter was ($7.1) million, and included scientific and business development expenditure of $4.2 million.

 

 

 

 

 

 

 

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

 

Company	Investor relations	United States
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au	Tiberend Strategic Advisors, Inc. Joshua Drumm, Ph.D. (Investors) Tel: +1 212 375 2664 Email: jdrumm@tiberend.com   Andrew Mielach (Media) Tel: +1 212 375 2694 Email: amielach@tiberend.com

 

About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.